Table 2.
Examples of nanomedicines that can be currently found in the industrial pharma development/sales.
| Drug Name (Tradename/Active Principle) | Company | Type of Nanoformulation | Indication/Route of Administration | Status |
|---|---|---|---|---|
| Abraxane/Paclitaxel | Abraxis (Warminster, Penn State, USA) and Celgene (Summit, New Jersey, USA) | Albumin nanoparticles | Various cancers/IV | Marketed |
| Adcetris/Brentuximab | Seattle Genetics (Bothell, Washington, USA) | Antibody-drug conjugate | Non-Hodgkin lymphoma/IV | Marketed |
| ALN-TTR02 (Patisiran)/siRNA | Alnylam Pharmaceuticals (Cambridge, Massachussets, USA) | Liposome | Transthyretin amyloidosis/IV | Phase II |
| AmBisome/Amphotericine B | Astellas Pharma (Chuo, Tokio, Japan) | Liposomes | Fungal infections/IV | Marketed |
| Aurimune/--- | Cytimmune sciences (Rockville, MD, USA) | Colloidal gold | Solid tumors/IV | Phase I/II |
| Auroshell/--- | Nanospectra Biosciences (Houston, Texas, USA) | Gold-silica nanoshells | Lung cancer/IV | Phase I |
| BIND-014/Docetaxel | Bind Therapeutics (Cambridge, Massachussets, USA) | Polymeric NPs | Solid tumors/IV | Phase II |
| Caelyx/Doxorubicin | Janssen (Beerse, Belgium) | PEGylated liposome | Solid tumors/IV | Marketed |
| DaunoXome/Daunorubicin | Galen Limited (Portadown, United Kingdom) | Liposome | Solid tumors/IV | Marketed |
| Diprivan/Propofol | AstraZeneca (London, United Kingdom) | Nano-emulsion | Anesthetic/IV | Marketed |
| Doxil/Doxorubicin | Janssen (Beerse, Belgium) | PEGylated liposomes | Various cancers/IV | Marketed |
| Eligard/Leuprorelina | Tolmar (Fort Collins, Colorado, USA) | PEGylated polymeric NPs | Prostate cancer/IV | Marketed |
| Emend/Aprepitant | Merck (Darmstadt, Germany) | Nanocrystal | Anti-emetic/Oral | Marketed |
| Genexol-PM/Paclitaxel | Samyang Biopharm (Seongnam, South Korea) | PEG-PLA polymeric micelles | Various cancers/IV | Marketed |
| Invega sustenna/Paliperidone palmitate | Janssen (Beerse, Belgium) | Nanocrystal | Schizophrenia/IM | Marketed |
| Ivac-MUTANOME/specific mRNAs | BioNTech (Mainz, Germany) | mRNA vaccine | Breast cancer and melanoma/Intranodal | Phase I |
| L-490/Insulin | Merck (Darmstadt, Germany) | Polymeric nanoparticles | Diabetes type I/SC | Phase I |
| Lipotecan/Camptotethin | Taiwan liposome (Taipei, Taiwan) | Polymeric micelles | Various cancers/IV | Phase I/II |
| Marqibo/Vincristine | Talon therapeuticals (Mississauga, Ontario, Canada) | Sphingomyelin -based liposomes | Leukemia and melanoma/IV | Marketed |
| Megace ES/Megestrol | Par Pharmaceuticals (Woodcliff Lake, New Jersey, USA) | Nanocrystal | Anti-anorexic/Oral | Marketed |
| Myocet/Doxorubicin | Teva Pharmaceuticals (Pétah Tiqvà, Israel) | Liposome | Various tumors/IV | Marketed |
| NC-6004/Cisplatine | NanoCarrier Co. (Kashiwa, Chilba, Japan) | Micelle | Lung cancer/IV | Phase I/II |
| Oncaspar/Pegaspargase | Enzon Pharmaceuticals (Farmingdale, New York, USA) | Polymer-protein conjugate | Acute Lymphoblastic leukemia (ALL)/IM or IV | Marketed |
| Oncoprex/pDNA TUSC2 | GenPrex (Austin, Texas, USA) | Liposomes | Lung cancer/IV | Phase II |
| Onivyde/Irinotecan | Merrimack Pharmaceuticals (Cambridge, Massachussets, USA) | PEGylated liposomes | Pancreatic metastatic cancer/IV | Marketed |
| Ontak/Denileukin diftitox | Seragen (Madrid, Spain) | Protein NPs | Various tumors/IV | Marketed |
| Rapamune/Rapamycin | Wyeth/Pfizer (Philadelphia, Penn State, USA) | Nanocrystal | Immunosuppressive/Oral | Marketed |
| Tocosol/Paclitaxel | Oncogenex Technologies (Bothell, Washington, USA) | Nano-emulsion | Various tumors/IV | Marketed |
| Tricor/Fenofibrate | Abbott (Chicago, Illinois, USA) | Nanocrystal | Hypercholesterolemia/Oral | Marketed |
| ---/siRNA PCSK9 synthesis inhibitor | Alnylam/Tekmira (Cambridge, Massachussets, USA) | Lipid NPs | Hypercholesterolemia/IV | Phase I |
| ---/siRNA transthyretin inhibitor | Alnylam/Tekmira (Cambridge, Massachussets, USA) | Lipid NPs | Amyloidosis/IV | Phase II |
IV: Intravenous; NPs: nanoparticles; PEG: poly(ethylene glycol); PLA: poly (lactic acid).